Skip to main content

Table 3 Objective responses to amulirafusp alfa in the Lugano EFS (n = 46)

From: Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

Response

FL (n = 20), n (%)

DLBCL (n = 14), n (%)

MZL (n = 7), n (%)

Total (n = 46), n (%)

Objective response

7 (35.0)

1 (7.1)

2 (28.6)

10 (21.7)

Disease control

13 (65.0)

5 (35.7)

5 (71.4)

24 (52.2)

CR

4 (20.0)

0

1 (14.3)

5 (10.9)

PR

3 (15.0)

1 (7.1)a

1 (14.3)b

5 (10.9)

SD

6 (30.0)

4 (28.6)

3 (42.9)

14 (30.4)

PD

7 (35.0)

9 (64.3)

2 (28.6)

22 (47.8)

  1. aThis is a patient with primary bone DLBCL; bThis is a patient with MALT-L
  2. CR complete response, DLBCL diffuse large B-cell lymphoma, EFS efficacy set, FL follicular lymphoma, MALT-L mucosa-associated lymphoid tissue lymphoma, MZL marginal zone lymphomas, n number of patients included in statistical analyses, PD progressive disease, PR partial response, SD stable disease